BUY Biocon Ltd — Manas Jaiswal
byManas JaiswalHorizon: NA (inferred Swing (≤2wk))6 Jul 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days
Advisor consensus · same horizon·6 Jul · today
Biocon Ltd completed the acquisition of 1,15,36,956 equity shares of its material subsidiary, Biocon Biologics Limited (BBL), from 127 selling shareholders. In consideration, Biocon allotted 87,86,362
BSE · Company Update·29 Jun · 6d ago
Nothing found in this tip’s window yet.
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Biocon
- BUY — Kunal Bothra22 Oct 2026 · ~2 weeks · target ₹345 · SL hit
- SELL — Rajesh Satpute9 Oct 2026 · ~3 months · target ₹335 · Active
- BUY — Axis Securities19 Sept 2026 · ~3 months · target ₹424 · Active
- BUY — Prakash Gaba17 Sept 2026 · ~2 weeks · target ₹390 · Target hit
- BUY — Vikas Salunkhe, Nirmal Bang Securities27 Aug 2026 · ~2 weeks · target ₹440 · SL hit
More from Manas Jaiswal
- BUY Ajanta Pharma23 Oct 2026 · Same day · target ₹3,425 · SL hit
- BUY Torrent Pharmaceuticals23 Oct 2026 · Same day · target ₹4,725 · SL hit
- BUY SAGILITY23 Oct 2026 · ~2 weeks · target ₹50 · SL hit
- BUY Zydus Lifesciences22 Oct 2026 · ~3 months · target ₹1,160 · SL hit
- BUY IPCA Laboratories22 Oct 2026 · ~2 weeks · target ₹2,000 · Active

